7498 Results (Page 291 of 300)
Pharmaceuticals Markets Research Reports
Malaysia Exosome Research Market Analysis
The Malaysia Exosome Research Market was valued at $0.2 Mn in 2023 and is projected to grow at a CAGR of 16.2% from 2023 to 2023, to $0.8 Mn by 2030. The key drivers of this industry are increasing prevalence and incidences of cancer and various auto-immune diseases, rising healthcare expenditure for better health services, growing R&D activities associated with exosome research, technological advancements in exosome isolation and analytical procedures, and increasing advanced applications of exosomes. The industry is primarily dominated by players such as Revery International Group Berhad, Thermo Fisher Scientific, Roche, System Biosciences LLC, Capricor Therapeutic among others.
Canada Cough Hypersensitivity Syndrome Therapeutics Market Analysis
The Canada Cough Hypersensitivity Syndrome Therapeutics Market was valued at $0.648 Bn in 2022 and is predicted to grow at a CAGR of 5.9% from 2023 to 2030, to $1.025 Bn by 2030. The key drivers of this industry include the increasing prevalence of Cough Hypersensitivity Syndrome, growing awareness and diagnosis, and the emergence of advanced therapeutics in the industry. The industry is primarily dominated by players such as Teva, Pfizer, Novartis, Johnson & Johnson, and GSK among others.
China Cough Hypersensitivity Syndrome Therapeutics Market Analysis
The China Cough Hypersensitivity Syndrome Therapeutics Market was valued at $0.651 Bn in 2022 and is predicted to grow at a CAGR of 7.4% from 2023 to 2030, to $1.153 Bn by 2030. The key drivers of this industry include the increasing prevalence of Cough Hypersensitivity Syndrome, the development of advanced therapeutics, and expanding healthcare infrastructure. The industry is primarily dominated by players such as Johnson & Johnson, GSK, Merck, Novartis, AstraZeneca, and Pfizer among others.
France Cough Hypersensitivity Syndrome Therapeutics Market Analysis
The France Cough Hypersensitivity Syndrome Therapeutics Market was valued at $223 Mn in 2022 and is predicted to grow at a CAGR of 4.9% from 2023 to 2030, to $327 Mn by 2030. The main factors driving this industry include the rising prevalence of Cough Hypersensitivity Syndrome, supportive government initiatives, and the development of advanced therapeutics. The industry is primarily dominated by players such as Roche, Pfizer, Sanofi, Novartis, Johnson & Johnson, and GSK among others.
Mexico Lipid Disorder Therapeutics Market Analysis
The Mexico Lipid Disorder Therapeutics Market was valued at $60.6 Mn in 2023 and is predicted to grow at a CAGR of 12.63% from 2023 to 2030, to $139.3 Mn by 2030. Mexico Lipid Disorder Therapeutics Market is growing due to Growing Awareness and Diagnosis Rates, Collaborations, Partnerships, and Increasing Healthcare Expenditure. The industry is primarily dominated by players such as Sanofi, Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Viatris, AstraZeneca PLC, and Dr. Reddys Laboratories Ltd.
Germany Cough Hypersensitivity Syndrome Therapeutics Market Analysis
The Germany Cough Hypersensitivity Syndrome Therapeutics Market was valued at $296 Mn in 2022 and is predicted to grow at a CAGR of 4.1% from 2023 to 2030, to $409 Mn by 2030. The key drivers of this industry include the increasing prevalence of Cough Hypersensitivity Syndrome, expanding government initiatives, and high unmet medical needs. The industry is primarily dominated by players such as Roche, Pfizer, Teva, Novartis, Johnson & Johnson, and GSK among others.
Indonesia Cough Hypersensitivity Syndrome Therapeutics Market Analysis
The Indonesia Cough Hypersensitivity Syndrome Therapeutics Market was valued at $49 Mn in 2022 and is predicted to grow at a CAGR of 5.9% from 2023 to 2030, to $77 Mn by 2030. The primary factors propelling this sector comprise the rising prevalence of Cough Hypersensitivity Syndrome, the development of advanced therapeutics, and improving healthcare access. The industry is primarily dominated by players such as Johnson & Johnson, GSK, Sanofi, Novartis, AstraZeneca, Pfizer, and Boehringer Ingelheim among others.
Spain Lipid Disorder Therapeutics Market Analysis
Spain Lipid Disorder Therapeutics Market was valued at $12.1 Mn in 2023 and is predicted to grow at a CAGR of 13.23% from 2023 to 2030, to $28.9 Mn by 2030. Spain Lipid Disorder Therapeutics Market is growing due to Customer preferences, Advancements in Therapeutics, Increased Healthcare Expenditure, and Macroeconomic factors. The industry is primarily dominated by players such as Novartis AG, Sanofi, Pfizer, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., AbbVie, Inc., Viatris, AstraZeneca PLC, and Dr. Reddys Laboratories Ltd.
Mexico Cough Hypersensitivity Syndrome Therapeutics Market Analysis
The Mexico Cough Hypersensitivity Syndrome Therapeutics Market was valued at $122 Mn in 2022 and is predicted to grow at a CAGR of 6.15% from 2023 to 2030, to $196 Mn by 2030. The main factors driving this industry include the increasing prevalence of Cough Hypersensitivity Syndrome, expanding healthcare infrastructure, and the development of advanced therapeutics. The industry is primarily dominated by players such as Roche, Pfizer, Teva, Novartis, Johnson & Johnson, and GSK among others.
UK Lipid Disorder Therapeutics Market Analysis
The UK Lipid Disorder Therapeutics Market was valued at $16.2 Mn in 2023 and is predicted to grow at a CAGR of 12.83% from 2023 to 2030, to $37.8 Mn by 2030. UK Lipid Disorder Therapeutics Market is growing due to the Increasing Prevalence of Cardiovascular Diseases, Government & NHS Support, Technological Advancements, and Personalized Medicine. The industry is primarily dominated by players such as Sanofi, Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Viatris, AstraZeneca PLC, and Dr. Reddys Laboratories Ltd.
Saudi Arabia Cough Hypersensitivity Syndrome Therapeutics Market Analysis
The Saudi Arabia Cough Hypersensitivity Syndrome Therapeutics Market was valued at $138 Mn in 2022 and is predicted to grow at a CAGR of 7.4% from 2023 to 2030, to $244 Mn by 2030. The key drivers of this industry include the surge in prevalence of Cough Hypersensitivity Syndrome, supportive government initiatives, and the emergence of novel therapeutics. The industry is primarily dominated by players such as Sanofi, Pfizer, Almirall, Novartis, Johnson & Johnson, and GSK among others.
Indonesia Lipid Disorder Therapeutics Market Analysis
Indonesia Lipid Disorder Therapeutics Market was valued at $369.7 Mn in 2023 and is predicted to grow at a CAGR of 10.83% from 2023 to 2030, to $759.3 Mn by 2030. Indonesia Lipid Disorder Therapeutics Market is growing due to Shifting Demographics, Growing Awareness, and Increasing Healthcare Expenditure. The industry is primarily dominated by players such as Sanofi, Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Viatris, AstraZeneca PLC, and Dr. Reddys Laboratories Ltd.
Spain Cough Hypersensitivity Syndrome Therapeutics Market Analysis
The Spain Cough Hypersensitivity Syndrome Therapeutics Market was valued at $156 Mn in 2022 and is predicted to grow at a CAGR of 4.9% from 2023 to 2030, to $229 Mn by 2030. The key drivers of this industry include the surge in the prevalence of Cough Hypersensitivity Syndrome, the emergence of advanced therapeutics, and the growing focus on patient-centered outcomes. The industry is primarily dominated by players such as Roche, Pfizer, Wyeth, Novartis, Johnson & Johnson, and Takeda among others.
Japan Lipid Disorder Therapeutics Market Analysis
The Japan Lipid Disorder Therapeutics Market was valued at $277.8 Mn in 2023 and is predicted to grow at a CAGR of 11.63% from 2023 to 2030, to $600 Mn by 2030. Japan Lipid Disorder Therapeutics Market is growing due to the Rising Prevalence of Cardiovascular Disease, Growing Awareness, and Government Initiatives, and Technological Advancements. The industry is primarily dominated by players such as Sanofi, Sun Pharmaceutical Industries Ltd.Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Viatris, AstraZeneca PLC, and Dr. Reddys Laboratories Ltd.
UAE Cough Hypersensitivity Syndrome Therapeutics Market Analysis
The UAE Cough Hypersensitivity Syndrome Therapeutics Market was valued at $41 Mn in 2022 and is predicted to grow at a CAGR of 6.9% from 2023 to 2030, to $69 Mn by 2030. The key drivers of this industry include the rising prevalence of Cough Hypersensitivity Syndrome, supportive government initiatives, and the development of novel therapeutics. The industry is primarily dominated by players such as Sanofi, Pfizer, Akorn, Novartis, Johnson & Johnson, and GSK among others.
Malaysia Lipid Disorder Therapeutics Market Analysis
The Malaysia Lipid Disorder Therapeutics Market was valued at $194.9 Mn in 2023 and is predicted to grow at a CAGR of 11.63% from 2023 to 2030, to $421.1 Mn by 2030. Malaysia Lipid Disorder Therapeutics Market is growing due to Sedentary Lifestyles, Public Awareness and Early Intervention, Innovation, and New Treatment Options. The industry is primarily dominated by players such as Pharmaniaga Berhad, Sanofi, Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Viatris, AstraZeneca PLC, and Dr. Reddys Laboratories Ltd.
UK Cough Hypersensitivity Syndrome Therapeutics Market Analysis
The UK Cough Hypersensitivity Syndrome Therapeutics Market was valued at $211 Mn in 2022 and is predicted to grow at a CAGR of 3.9% from 2023 to 2030, to $286 Mn by 2030. The key drivers of this industry include the rising prevalence of Cough Hypersensitivity Syndrome, the evolving treatment landscape, and supportive regulatory policies. The industry is primarily dominated by players such as Johnson & Johnson, GSK, Merck, Novartis, AstraZeneca, and Pfizer among others.
Singapore Lipid Disorder Therapeutics Market Analysis
The Singapore Lipid Disorder Therapeutics Market was valued at $171.7 Mn in 2023 and is predicted to grow at a CAGR of 14.13% from 2023 to 2030, to $433.1 Mn by 2030. Singapore Lipid Disorder Therapeutics Market is growing due to the Prevalence of Cardiovascular Diseases, Growing Awareness, and Advancements in Therapeutics. The industry is primarily dominated by players such as Sanofi, GlaxoSmithKline plc, Pfizer, Inc., Novartis AG, Merck & Co., Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Viatris, AstraZeneca PLC, and Dr. Reddys Laboratories Ltd.
US Cough Hypersensitivity Syndrome Therapeutics Market Analysis
The US Cough Hypersensitivity Syndrome Therapeutics Market was valued at $3.402 Bn in 2022 and is predicted to grow at a CAGR of 3.9% from 2023 to 2030, to $4.620 Bn by 2030. The primary factors propelling this industry comprise the rising prevalence of Cough Hypersensitivity Syndrome, growing awareness, and high unmet medical needs. The industry is primarily dominated by players such as Teva, Pfizer, Vertex, Novartis, Johnson & Johnson, and GSK among others.
Philippines Lipid Disorder Therapeutics Market Analysis
The Philippines Lipid Disorder Therapeutics Market was valued at $50.5 Mn in 2023 and is predicted to grow at a CAGR of 13.63% from 2023 to 2030, to $123.5 Mn by 2030. Philippines Lipid Disorder Therapeutics Market is growing due to the Rising Prevalence of Cardiovascular Diseases, Growing Awareness, Government Initiatives, and funding. The industry is primarily dominated by players such as Sanofi, Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Viatris, AstraZeneca PLC, and Dr. Reddys Laboratories Ltd.
Brazil Constipation Therapeutics Market Analysis
Brazil Constipation Therapeutics Market was valued at $455 Mn in 2022 and is estimated to reach $811 Mn in 2030, exhibiting a CAGR of 7.5% during the forecast period. The constipation therapeutics market is growing driven by the global rise in constipation prevalence associated with aging, sedentary lifestyles, and poor dietary habits, and further fuelled by an expanding elderly population more prone to chronic conditions. Key players in this industry include AbbVie, Allergan, Boehringer Ingelheim, EMS, Farmoquímica, Grünenthal, Johnson & Johnson, Norgine, Pfizer, and Sanofi.
Vietnam Lipid Disorder Therapeutics Market Analysis
The Vietnam Lipid Disorder Therapeutics Market was valued at $28.3 Mn in 2023 and is predicted to grow at a CAGR of 14.13% from 2023 to 2030, to $71.3 Mn by 2030. Vietnam Lipid Disorder Therapeutics Market is growing due to the Rising Prevalence of Non-Communicable Diseases, Growing Awareness and Focus on Chronic Disease Management, and Increasing Healthcare Expenditure. The industry is primarily dominated by players such as Boehringer Ingelheim, Sanofi, Sun Pharmaceutical Industries Ltd., Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Viatris, AstraZeneca PLC, and Dr. Reddys Laboratories Ltd.
France Actinic Keratosis Therapeutic Market Analysis
The France Actinic Keratosis Therapeutic Market is projected to grow at a CAGR of 3.9%, increasing from $187 Mn in 2022 to reach $254 Mn by the year 2030. Actinic Keratosis is becoming more common, and there are a number of reasons for this, such as more awareness and changing lifestyles, improved diagnostic tools, prolonged exposure and aging populations, and increased focus on skin health. The key players in the French market include Galderma, Almirall, Sun Pharma, Novartis, Pierre Fabre Laboratories, LFB Biotechnologies etc.
China Constipation Therapeutics Market Analysis
China Constipation Therapeutics Market was valued at $1463 Mn in 2022 and is estimated to reach $2708 Mn in 2030, exhibiting a CAGR of 8% during the forecast period. The constipation therapeutics market is experiencing growth driven by the rising prevalence of constipation worldwide, attributed to factors like aging, sedentary lifestyles, and unhealthy dietary habits, with the expanding elderly population, more prone to chronic conditions, further contributing to this market expansion. Notable participants in this industry include Pfizer, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Merck & Co., Novartis, Sanofi, Takeda, Shanghai Fosun Pharmaceutical, and Beijing Tongrentang.
Kenya Lipid Disorder Therapeutics Market Analysis
Kenya Lipid Disorder Therapeutics Market was valued at $7.1 Mn in 2023 and is predicted to grow at a CAGR of 13.73% from 2023 to 2030, to $17.4 Mn by 2030. Kenya Lipid Disorder Therapeutics Market is growing due to Increasing Healthcare Expenditure, the Rising Prevalence of Cardiovascular Diseases (CVDs), Public Awareness, and Early Intervention. The industry is primarily dominated by players such as Sanofi, Sun Pharmaceutical Industries Ltd., Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Viatris, AstraZeneca PLC, and Dr. Reddys Laboratories Ltd.
